RNA-based therapeutics represent a promising new frontier in Alzheimer's disease (AD) treatment, offering the potential to directly target the underlying genetic and molecular drivers of the disease. This category encompasses multiple therapeutic modalities including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), RNA aptamers, and microRNA-based approaches, each targeting different aspects of AD pathogenesis including amyloid-beta production, tau pathology, and neuroinflammation.
**RNA Therapeutic Modalities**
Modality
Mechanism
Advantages
Challenges
Antisense Oligonucleotides Bind mRNA to block translation or degrade target
Long-lasting effect, precise targeting
Delivery to brain
SiRNA Trigger RNA-induced silencing
Potent gene knockdown
Complex delivery
RNA Aptamers Bind specific protein targets
High specificity
Selection process
MicroRNA Therapies Modulate multiple disease pathways
Broad effects
Off-target risks
ASOs are single-stranded DNA sequences that bind to complementary messenger RNA (mRNA) through Watson-Crick base pairing. This binding can:
Steric Block : Prevent translation by blocking ribosome assemblyRNase H-Mediated Degradation : recruit RNase H to cleave the RNA strandSplice Modulation : Alter pre-mRNA splicing patterns
IONIS-APPRx : ASO targeting APP mRNA to reduce Aβ productionBIIB037 : Related APP-targeting ASO in development
IONIS-MAPT : ASO targeting all tau isoformsReduces both 3R and 4R tau expression
IONIS-BACE1 : ASO targeting beta-secretase Reduces amyloidogenic processing
Drug
Target
Company
Stage
Indication
IONIS-APP
APP
Ionis/Biogen
Phase 1/2
AD
IONIS-MAPT
Tau
Ionis/Roche
Phase 1/2
AD
BIIB080
Tau
Biogen
Phase 1
AD
SiRNA therapeutics face significant challenges for CNS delivery:
Blood-Brain Barrier Neuronal Uptake : Must enter target neurons Off-Target Effects : Must minimize unintended gene silencing
Conjugate Approaches : GalNAc conjugates for liver deliveryViral Vectors : AAV-mediated siRNA deliveryNon-Viral Nanoparticles : Lipid nanoparticlesDirect CNS Delivery : Intrathecal or intraventricular administration
Anti-Amyloid siRNA : Targeting BACE1, APP, gamma-secretase Anti-Tau siRNA : Targeting MAPT expressionAnti-Inflammatory siRNA : Targeting TLRs, IL-1β
Alnylam : siRNA programs for ADSilence Therapeutics : siRNA delivery platformsDicerna : GalNAc-siRNA conjugates
RNA aptamers are single-stranded RNA molecules that bind specific molecular targets with high affinity and specificity. They function similarly to antibodies but offer advantages:
Smaller Size : Better tissue penetrationChemical Synthesis : Easier manufacturingThermal Stability : Broader storage conditionsLower Immunogenicity : Reduced immune response
Aptamers that bind Aβ monomers and oligomers
Prevent aggregation and toxic species formation
Could serve as diagnostic tools
Anti-tau aptamers under development
Block tau-tau interactions
Prevent spread of pathology
MicroRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally. In AD, multiple miRNAs are dysregulated:
miR-29 : Targets BACE1miR-124 : Neuronal-specific, involved in synaptic functionmiR-146a : Neuroinflammation regulation
miRNA Antagonists : Block pathogenic miRNAsmiRNA Mimics : Restore beneficial miRNAs
Focus : Antisense oligonucleotidesPartnerships : Biogen, Roche, AstraZenecaKey Programs : APP, Tau, BACE1 ASOs
Focus : SiRNA therapeuticsDelivery Platform : GalNAc conjugationCNS Strategy : Advanced delivery technologies
Focus : CNS RNA therapeuticsPartnership : Ionis collaborationKey Programs : BIIB080 (tau), others
Focus : Stereopure oligonucleotidesPlatform : PRISM™ technologyAD Programs : Various RNA targets
Focus : ASO for ADTechnology : PATrOL™ platform
Focus : RNAi therapeuticsDelivery : Targeted delivery technology
Focus : RNA aptamersTechnology : SELEX platform
Focus : mRNA therapeuticsAD Program : mRNA-based protein replacement
Company
Platform
Focus Area
Clinical Stage
Ionis
ASO
APP, Tau, BACE1
Phase 1/2
Alnylam
siRNA
Multiple targets
Preclinical
Biogen
ASO
Tau
Phase 1
Wave
ASO
Multiple targets
Discovery
Moderna
mRNA
Protein delivery
Discovery
¶ Challenges and Future Directions
Blood-Brain Barrier Delivery : Most significant barrierDose Optimization : Balancing efficacy and safetyLong-term Safety : Unknown effects of chronic gene modulationPatient Selection : Identifying optimal patient populations
Conjugate Technologies : Improved brain targetingGene Therapy Vectors : AAV-delivered RNA therapeuticsDirect CNS Delivery : Intrathecal administrationCombination Approaches : RNA + small molecule
The field of RNA-based AD therapeutics is advancing rapidly:
Personalized Medicine : Genetic stratification for targeted therapyDisease Modification : Earlier intervention with preventive therapyCombination Approaches : RNA therapeutics with other modalitiesBiomarker Development : Patient selection and monitoring